These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


151 related items for PubMed ID: 18046224

  • 1. Predicted biologic activity of intravitreal bevacizumab.
    Stewart MW.
    Retina; 2007; 27(9):1196-200. PubMed ID: 18046224
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Predicted biological activity of intravitreal VEGF Trap.
    Stewart MW, Rosenfeld PJ.
    Br J Ophthalmol; 2008 May; 92(5):667-8. PubMed ID: 18356264
    [Abstract] [Full Text] [Related]

  • 4. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.
    Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X, Tübingen Bevacizumab Study Group, Grisanti S.
    Ophthalmology; 2008 Oct; 115(10):1750-5, 1755.e1. PubMed ID: 18708261
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of intravitreal ranibizumab (Lucentis).
    Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ.
    Ophthalmology; 2007 Dec; 114(12):2179-82. PubMed ID: 18054637
    [Abstract] [Full Text] [Related]

  • 6. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients.
    Beer PM, Wong SJ, Hammad AM, Falk NS, O'Malley MR, Khan S.
    Retina; 2006 Oct; 26(8):871-6. PubMed ID: 17031285
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes.
    Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K, Ohji M.
    Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1606-8. PubMed ID: 19875666
    [Abstract] [Full Text] [Related]

  • 8. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
    Arimura N, Otsuka H, Yamakiri K, Sonoda Y, Nakao S, Noda Y, Hashiguchi T, Maruyama I, Sakamoto T.
    Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
    [Abstract] [Full Text] [Related]

  • 9. Serum concentration of bevacizumab after intravitreal injection in experimental branch retinal vein occlusion.
    Chuang LH, Wu WC, Yeung L, Wang NK, Hwang YS, Chen KJ, Kuo JZ, Lai CC.
    Ophthalmic Res; 2011 May; 45(1):31-5. PubMed ID: 20714188
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.
    Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K, Nugent AK, Hirooka K, Baba T.
    Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4807-13. PubMed ID: 19324856
    [Abstract] [Full Text] [Related]

  • 11. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans.
    Meyer CH, Krohne TU, Holz FG.
    Retina; 2011 Oct; 31(9):1877-84. PubMed ID: 21738089
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of intravitreal bevacizumab (Avastin).
    Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ.
    Ophthalmology; 2007 May; 114(5):855-9. PubMed ID: 17467524
    [Abstract] [Full Text] [Related]

  • 13. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration.
    Abrishami M, Zarei-Ghanavati S, Soroush D, Rouhbakhsh M, Jaafari MR, Malaekeh-Nikouei B.
    Retina; 2009 May; 29(5):699-703. PubMed ID: 19430280
    [Abstract] [Full Text] [Related]

  • 14. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.
    Fintak DR, Shah GK, Blinder KJ, Regillo CD, Pollack J, Heier JS, Hollands H, Sharma S.
    Retina; 2008 May; 28(10):1395-9. PubMed ID: 18827737
    [Abstract] [Full Text] [Related]

  • 15. Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy.
    Hattori T, Shimada H, Nakashizuka H, Mizutani Y, Mori R, Yuzawa M.
    Retina; 2010 May; 30(5):761-4. PubMed ID: 20453802
    [Abstract] [Full Text] [Related]

  • 16. Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes.
    Wu WC, Lai CC, Chen KJ, Chen TL, Wang NK, Hwang YS, Yeung L, Li LM.
    Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3701-8. PubMed ID: 20181842
    [Abstract] [Full Text] [Related]

  • 17. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.
    Chang TS, Kokame G, Casey R, Prenner J, Feiner L, Anderson N.
    Retina; 2009 Oct; 29(9):1235-41. PubMed ID: 19934818
    [Abstract] [Full Text] [Related]

  • 18. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections.
    Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis AI, Liotsou A, Vergados I.
    Retina; 2009 Mar; 29(3):313-8. PubMed ID: 19287287
    [Abstract] [Full Text] [Related]

  • 19. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema.
    Roh MI, Kim HS, Song JH, Lim JB, Kwon OW.
    Ophthalmology; 2009 Jan; 116(1):80-6. PubMed ID: 19118699
    [Abstract] [Full Text] [Related]

  • 20. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements.
    Shah AR, Del Priore LV.
    Br J Ophthalmol; 2009 Aug; 93(8):1027-32. PubMed ID: 19429594
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 8.